Vertex Pharmaceuticals Incorporated VRTX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.44B | 3.33B | 2.99B | 3.19B | 3.08B |
| Total Other Revenue | -- | -- | -- | 0.00 | -- |
| Total Revenue | 3.44B | 3.33B | 2.99B | 3.19B | 3.08B |
| Cost of Revenue | 1.58B | 1.48B | 1.35B | 1.44B | 1.39B |
| Gross Profit | 1.87B | 1.85B | 1.63B | 1.75B | 1.68B |
| SG&A Expenses | 641.10M | 582.20M | 493.70M | 487.00M | 445.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.22B | 2.07B | 1.85B | 1.93B | 1.84B |
| Operating Income | 1.22B | 1.27B | 1.14B | 1.26B | 1.24B |
| Income Before Tax | 783.40M | 1.39B | 1.25B | 1.33B | 1.30B |
| Income Tax Expenses | 129.80M | 292.00M | 221.50M | 139.90M | 215.90M |
| Earnings from Continuing Operations | 653.60M | 1.10B | 1.03B | 1.19B | 1.08B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 653.60M | 1.10B | 1.03B | 1.19B | 1.08B |
| EBIT | 1.22B | 1.27B | 1.14B | 1.26B | 1.24B |
| EBITDA | 1.29B | 1.33B | 1.19B | 1.29B | 1.29B |
| EPS Basic | 2.58 | 4.34 | 4.06 | 4.69 | 4.24 |
| Normalized Basic EPS | 3.19 | 3.50 | 3.07 | 3.40 | 3.31 |
| EPS Diluted | 2.56 | 4.31 | 4.02 | 4.65 | 4.20 |
| Normalized Diluted EPS | 3.16 | 3.48 | 3.05 | 3.37 | 3.28 |
| Average Basic Shares Outstanding | 253.50M | 253.70M | 254.10M | 253.90M | 255.60M |
| Average Diluted Shares Outstanding | 255.20M | 255.20M | 256.30M | 256.10M | 257.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |